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Abstract 
Background: Diabetes treatment requires specialized multi-professional teams, supplies for blood glucose monitor-
ing and training for self-injections of human insulin or insulin analogues. The State Health Secretariat of the Federal 
District (SHS-FD) has dispensed insulin analogues by means of clinical validated protocols since 2004. However, data 
on outcomes of follow-up are still unknown.
Objective: To evaluate the results of glycated hemoglobin (HbA1c) among diabetic patients treated with insulin 
analogues.
Methods: It is a retrospective cohort study involving data of type 1(DM1) and type 2 diabetes (DM2) patients 
18 years old and above who were registered to participate at the insulin analogues dispense program of the SHS-FD. 
Evaluation of criteria of insulin treatment continuity was based on HbA1c values achieved in the follow-up period: in 
the target, <7 %, patients between 18 and 65 years old; <8 % for those above 65 years old; out of target, when values 
were superior these cut off points for both age groups; and minimum 0.5 % reduction of two HbA1c values during 
follow-up.
Results: Two hundred and fifteen formularies were analyzed: Type 2 patients (63.7 %) and female sex were the most 
prevalent (63.7 %), (p < 0.05). Mean age and SD were 41.5 ± 23.5 years among DM1 and 60.5 ± 28.5 in those with 
DM2. HbA1c in the target was found in 26 %, 48 % were out of target and 26 % achieved 0.5 % minimum reduction in 
HbA1c value (p < 0.05). The main clinical characteristics associated with HbA1c found to be in the target were older 
age (>65 years), more than three medical appointments in the follow-up and lower mean HbA1c in the patient selec-
tion for inclusion criteria in the dispense program (p < 0.05).
Conclusion: The low number of patients using insulin analogues in the target group, considered to be in good 
control, implies the need to reevaluate both level of patients self-care knowledge and glucose monitoring prior their 
inclusion in the insulin analogue dispense program. Reinforcement and training of health professional teams in enroll-
ment procedures should be on mandatory basis to avoid protocol failure or deviations.
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Background
Insulin analogues have been dispensed to both type 1 
and type 2 diabetes patients for the last 10 years by the 
State Health Secretariat of the Federal District (SHS-
FD) in Brazil [1, 2]. The cost is high and covered by the 
Federal District Government budget. Insulin analogue 
dispense is based upon a validated clinical protocol, 
which has been regularly updated [2–6] and involves 
clinical features and glycated hemoglobin (HbA1c) tar-
gets to be analyzed every 6 months by the medical team 
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before being renewed. Currently, two long acting insulin 
analogues have been dispensed, glargine and detemir, 
and one of short acting analogues (lispro, aspart or 
glulisin).
Type 2 (DM2) treatment approach is by primary care 
teams of SHS-FD network and includes clinical and edu-
cation besides pharmaceutical supervision to deliver 
supplies and medications to all patients. Secondary and 
tertiary specialized health professional teams are respon-
sible to manage the care and therapy interventions for 
all DM1 patients and those on the continuous insulin 
infusion system (CIIS), DM2 patients who are mainly 
on insulin treatment, pregnant diabetic women, diag-
nosis procedures and follow-up of diabetic long term 
complications.
SHS-FD has long been evolving in the standard of care 
and assistance to diabetic patients since the Program of 
Education and Control of Diabetes (PECD) was set up 
in 1988 [7]. In 1994, a local law named Lei Distrital 640 
empowered the PECD coordinators to implement impor-
tant policies on primary care grounds including educa-
tional seminars for the health care providers to be able 
to educate patients at health centers. Moreover, the law 
claimed mandatory human insulin dispense, syringes, 
glucose strips and meters, all has been in the pharmaceu-
tical portfolio since 1995. Long acting analogue glargine 
use had been previously used at a hospital unit of SHS-
FD that participated as center of a national study [8]. Its 
positive result contributed to be available in 2005, right 
after short acting lispro (2004) and later, detemir (2007) 
[9].
These insulin analogues have not been approved to 
be dispensed by the Brazilian Ministry of Health which 
only registered intermediate acting human insulin NPH 
(neutral protamine Hagerdon) for basal therapy and short 
acting (rapid, regular) in RENAME (Relação Nacional de 
Medicamentos, National Medicines List), its official port-
folio [10].
It is well recognized the main positive and proved 
effects of insulin analogues on hypoglycemia reduction, 
glucose peaks and improvement in quality of life [1, 11–
13] of DM1 patients. Recent meta-analysis have also rein-
forced long acting efficacy, safety and positive cost effects 
with long acting insulins over NPH [14, 15].
Importantly to mention that, despite being dispensed 
in more than ten states in the country, there are no direct 
reports focusing the current situation of diabetic patients 
treated in the Brazilian Unified Health System (hereby 
SUS) with long and short acting insulin analogues. There-
fore, this study aims to evaluate the glycemic control 
by means of HbA1c results achieved by the registered 
patients treated with insulin analogues in the SUS of Fed-
eral District (SUS-FD).
Research design and methods
It is a retrospective cohort study involving DM1 and 
DM2 patients registered at Hospital Regional do Gama 
(HRG), a health district of SHS-FD, to use insulin ana-
logues, in the period of 2005–2012. It was approved by 
the Ethical Committee of the Foundation of Teaching 
and Research in Health Sciences (FEPECS, Foundation 
for Teaching and Research in the Health Sciences) of 
SHS-FD.
All registered inclusion and continuity forms for using 
insulin analogues and renewing every 6  months, since 
enrollment start in 2005, was collected from January to 
December 2013.
Sample involved active users of insulin analogues who 
had at least two HbA1c (High Perfomance Líquid Croma-
tography method) results after initiating treatment, aging 
18 years old or above, from either public or private health 
system. Exclusion criteria were pregnancy, hemoglobi-
nopathy, insulin analogue detemir use (small dispense 
number of this other available long acting analogue) and 
for multivariate analysis, twenty-nine patients without 
using short acting insulin analogue were excluded from 
study.
Three groups of patient were set based on HbA1c: in 
the target, <7  % for diabetic patients between 18 and 
65  years old; <8  %, for those above 65  years old; out of 
target, values superior to cut off points for both age 
groups; minimum 0.5  % reduction, difference between 
of two HbA1c values achieved during follow-up with 
6  months interval. If any medical reason was found to 
explain a given patient not to reach the goal, he or she 
could be maintained in the analogue therapy until next 
scheduled clinical visit.
Statistical tests verified patient profile to HbA1c val-
ues as results of insulin analogues use. Mean, maximum, 
minimum and standard deviation (SD) were calculated. 
Chi square test (X2) to access categorical variables and 
Student T test to compare means, with 5 % statistical sig-
nificance. Multivariated analysis aimed to identify how 
selected variables related to HbA1c values during last 
evaluation; linear model without distinction of DM type. 
In order to reach better estimates, it was applied a robust 
model such as White’s heteroscedasticidade. Software 
Stata version 2.0 model was used for all tests. The esti-
mated model is shown below:
where HbA1c is the last value, α is the constant, Sex is 
the Duma, signalizes patient sex: 1—for female; 0—for 
male, Age is the patient age obtained at last evaluation, 
Combination is the dummy, signalizes if patient is treated 
HbA1c = α + β1sex+ β2age+ β3combination
+ β4insulin+ β5treatment duration
+ β6exam amount+ ε
Page 3 of 6Leite et al. Diabetol Metab Syndr  (2015) 7:66 
with combination of types of insulin analogues (short 
acting and glargine) or if he or she uses only one type. 1, 
combination, 0 if an exclusive type is used, Insulin is the 
total dose of insulin used by patient. If combination of 
short acting and glargine was used, total dose was sum of 
quantity of units of each insulin type, Duration of treat-
ment is the time that patient has been under treatment, 
based on the admission year in the programe, Quantity of 
exams is the quantity of appointments when HbA1c was 
verified, ε is the Model residual.
Results
Two hundred and fifteen diabetic patients were using insu-
lin analogues at the HRG. As shown in Additional file 1: 
Table  S1, DM1 was diagnosed in 78 (36.3  %) and DM2 
in 137 (63.7 %). Majority was female and they were diag-
nosed as DM2 compare to DM1 (p = 0.02). Mean age and 
SD were 41.5 ± 23.5 years for DM1 and 60.5 ± 28.5 years 
old for DM2 patients. Age stratification (18 to 34 and 35 to 
64 years old) showed similarities in DM1 group, and none 
was above 65  years old. DM2 patient distribution in the 
age groups from 35 to 64 years old and above 65 years old 
were similar, and there was only one patient between 18 
to 34 years old. Disease duration for both DM types over 
10 years was the most prevalent.
It is also shown in Additional file  1: Table  S1, major-
ity of sample took 31–60 UI of glargine insulin. A few 
DM1 users reported high glargine doses, unit amount 
ranged from 8 to 120 UI/day. Short acting insulin below 
30 UI was the most common dose (88.1 % in DM1 group 
and 69.7  % in DM2 group), and dose ranged from 3 to 
102 UI representing sum of insulin injections during the 
day. Dose register lacked in 29 patients. Proportion of 
basal–bolus regime (50–60  % of basal insulin and short 
acting 50–40 %), was verified in 64.4 % DM1 and in 50 % 
DM2 patients. Glargin insulin and short acting combi-
nation was found in 84 % of patients, while only glargin 
and short acting single use was observed in 14 and 2 %, 
respectively.
Additional file 2: Table S2 shows HbA1c results in rela-
tion to age, sex, insulin use and continuity criteria in both 
DM1 and DM2 patients. Mean HbA1c study sample was 
8.9 % (9.1 % for DM1 and 8.7 % for DM2). A significant 
difference of HbA1c was observed in the target group 
compare to the following situations: higher in those with 
a 0.5  % HbA1c minimum reduction (p  =  0.05); values 
were lower in DM1 women compare to those with DM2 
(p =  0.01). There were no statistical difference in other 
analysis.
In Additional file 3: Table S3 is shown the frequency of 
DM1 and DM2 according to sex and based in the conti-
nuity criteria of insulin analogue use. Minority of patients 
was in the target (26 %) or 0.5 % minimum reduction in 
HbA1c (26 %) (p = 0.001), most of them was out of tar-
get (48 %). There are significant percentage difference in 
the target group and those patients in out of target group 
(p = 0.001), out of target group compare to 0.5 % mini-
mum reduction of HbA1c values (p = 0.001) as well. On 
the other hand, patients out of target group versus those 
of 0.5 % minimum reduction group demonstrated no sig-
nificant difference in the HbA1c results (p = 0.89). DM1 
shows a significant lower initial mean HbA1c in the tar-
get group compare to those out of target (p = 0.03) and 
in the 0.5 % minimum reduction individuals (p = 0.003). 
There is a significant reduction of final HbA1c value 
compare to the initial HbA1c value (p =  0.01), no spe-
cific difference related to sex was verified only in those 
in the target group. As for DM2, initial mean HbA1c in 
the target group was significantly lower than in out of tar-
get (p = 0.009) group, and among those presenting 0.5 % 
minimum reduction of HbA1c (p = 0.001).
Additional file 4: Table S4 shows HbA1c multi-variation 
analysis of 186 patients concerning sex, age, insulin com-
bination treatment, total insulin dose, treatment dura-
tion and quantity of available exams. There is a positive 
relation among women who showed 0.63  % increment 
in the HbA1c values (p = 0.03). Age was a contributing 
factor favoring HbA1c lower values: 0.02  % significant 
reduction for each additional year (p = 0.01). Number of 
medical appointments also resulted in 0.26 % reduction 
of HbA1c (p = 0.01), as per appointment.
Discussion
This is a pioneer study, to our knowledge, which evalu-
ates results HbA1c of DM1 and DM2 individuals under 
treatment with insulin analogues dispensed in the SUS of 
Brazil. This research was performed at a hospital with a 
diabetes specialist team, providing secondary care in Fed-
eral District south region which comprising nearby cities 
from the Brazilian states of Minas Gerais and Goiás.
Since this is a retrospective study, it was not possible 
to access the socio-demographic data of patients, if from 
public or private sector, because these items were not 
included in the forms. Evaluation of diabetes education 
approach, that is part of the routine health care provi-
sion, was not an objective of the study.
Majority were women (63.7 %), particularly in the DM2 
group (69.3  %). It is important to emphasize that other 
Brazilian reports also show women to adhere to most 
of types of treatment [16], although it is not a finding in 
other studies [7, 17], which shows similar frequency of 
men and women as participants. There were an increased 
number of older DM2 individuals and it is in accordance 
to other population studies involving both types of DM 
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[18]. Diagnosis duration was lower in DM1 group com-
pare to DM2 group.
Insulin therapy only is one of main criteria to dispense 
insulin analogues in the SHS-FD protocol [2] and that 
was present in 84 % while 14 % used only insulin glargine. 
That is a disagreement to enroll patients in the protocol. 
However, short acting insulin only is justified for contin-
uous insulin infusion system (CIIS) or with NPH insulin, 
which comprised 2 % of sample.
Higher insulin doses of glargine and short acting ana-
logues (30 UI or more), as expected, were shown in the 
DM2 group. In a review study, mean glargine dose was 
30  UI [12], while in randomized control trials (RCT) 
a lower mean of 29.6 UI was verified [19]. A balance of 
glargine and short acting insulin doses was present in 
only 50 % of patients. That might have influenced HbA1c 
results.
Mean HbA1c was 8.9 %, lower than another Brazilian 
study whose mean was 9.1 and 40  % presented HbA1c 
above 9  % [20]. In the DM2 group, HbA1c mean was 
8.7 %, similar to HbA1c of a recent meta-analysis (8.6 %) 
[21]. Moreover, high HbA1c values during glargine treat-
ment have not been observed in other studies: 7.9  % 
[19], 7.1 % [22] values have been reported for DM2 while 
another study verified 8.0 % for DM1 [23].
There are controversies about the superiority of basal 
analogues to NPH therapy for DM2 [23] and while some 
reports have shown larger HbA1c decrease under glar-
gine use [14, 15, 22] others have found no superiority of 
glycemic control with analogues [21, 24].
In the present study 0.5  % minimum reduction of 
HbA1c was observed among 26  % of patients, which is 
the minimum cut off point for renewing and dispens-
ing insulin analogue in the SHS-FD protocol [2, 25, 26]. 
Other authors have considered a 1.0 % minimum reduc-
tion of HbA1c for a successful target of glargine use [27].
Protocol positive therapeutic response based on indi-
vidual’s age [28]. Thus, <7  % for individuals between 18 
and 65 years old and <8 % over 65 years old were achieved 
by 26 % of the whole sample and it was more frequent in 
DM2 (31.4 %) than in DM1 (16.7 %) group. These results 
are lower than other authors who showed HbA1c <7 % in 
50.3 % DM2 [22] and 57.7 % in DM2 patients plus cardio-
vascular risks [27].
In a cross-sectional multicenter Brazilian study, only 
13.2  % [20] and 10  % [16] of DM1 patients were in the 
target of HbA1c <7  % by means of different types of 
insulin therapy. In this study, frequency of those DM1 
under insulin analogue treatment in the target was higher 
(16.7  %) which suggests a real improvement after treat-
ment with glargine insulin. Another report showed that 
glargine use was similar to NPH, mixed insulin or lispro 
to achieve HbA1c less than 7 % in DM2 patients not well 
controlled with oral agents [24].
Majority of study patients did not achieve HbA1c tar-
get in the expected time before renewing dispense. Pro-
tocol allows maintenance of analogue continuity if special 
medical situations are related. It was verified in the tar-
get group initial lower HbA1c than both out of target or 
0.5 % minimum reduction groups. Previous reports show 
better control among diabetic patients who presents 
lower initial HbA1c [24].
Statistical model F test applied for multivariate analysis 
shows that all variables taken together explain variations 
verified in the HbA1c levels. Model can only explain 14 % 
variation that influenced HbA1c and was not included in 
the multivariate analysis. Patients well enrolled in pro-
gram proved benefit of continuity for achieving HbA1c 
targets and potentially hypoglycemia reduction and bet-
ter quality of life. Indeed, other studies have shown the 
necessity of evaluating glycemic variability [29, 30], indi-
vidualizing targets [31], and warning difficulty of treat-
ment and adherence as HbA1c only does not explain the 
complex factors of a success control [32].
Costs of treatment demands attention by health policy-
makers and managers. Lower glargine cost than NPH has 
been described in DM2 [33], but recent systematic review 
whose focus is mainly to point out costs [34], has sug-
gested that analogue insulins should not be dispensed in 
Minas Gerais, a state in the southeast of Brazil, or if so, it 
should request a negotiation with pharmaceutical indus-
try to reduce its price. Authors argue its price and differ-
ence to NPH cost have increased 291 and 536 % in recent 
years, respectively. They quote majority of glargine stud-
ies to be of “poor methodological quality or had high risk 
of bias”, and “there was no significant difference between 
glargine insulin and NPH insulins” [34]. That review arti-
cle did not consider other aspects of glargine treatment. 
According to another author [35], “it seems inappropri-
ate and flawed from the start as studies on glargine insu-
lin began in the late 1990s and not in 1970 besides data 
have been published since 2009”. Claims that five of eight 
papers selected for analysis were of poor quality and had 
risk of bias; one article compares two forms of insulin 
analogue delivery and not NPH; another study had only 
4  month duration; and hypoglycemia reduction, a gold-
standard outcomes of insulin analogues versus NPH, was 
not analyzed were also pointed out.
This study shows some limitation as it is a retrospective 
research and has not evaluated hypoglycemia. The HRG-
SHS/FD health district selected for this data analysis 
does not represent the entire socio-economical param-
eters of Federal District, neither the clinical practice 
reality of other health districts. These factors might have 
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influenced results and enrollment was inappropriate due 
the higher number of DM2 patients compare to DM1. 
That probably has biased the sample although protocol 
includes DM2 in special clinical situations and conditions 
only. Higher frequency of DM2 women also possibly 
influenced results related to gender.
Thus, clearly it is necessary to evaluate how health 
professionals have been enrolling participants and 
mandatory recall for protocol training as well. That 
potentially shall turn into a proper dispense and better 
surveillance of the insulin analogue program and pro-
vide means to a more adequate clinical follow-up. On 
the other hand, re-evaluation of self-care and SBGM 
should be carefully tailored among patients because 
dispense of insulins (of any type), glucose meters and 
strips seem not to be the main strategies unless edu-
cation is provided, as these issues have already been 
showed in other Brazilian studies on both DM1 and 
DM2 [16, 20].
This was a pioneer real-life study with insulin glar-
gine users and short acting analogues in the Brazilian 
SUS. It is valid to mention that patients were included 
at different times from the year 2005, when insulin 
glargine launched in the Brazilian market and a multi-
center study had finished in the country with positive 
results [8]. Later on, the preliminary Federal District 
experience reported the very first version of the SHS-
FD protocol [9]. Recently, Brazilian Ministry of Health 
also had to evaluate the inclusion of analogue insulins 
in its RENAME list [10], after a public audience. Its 
reports based on RCT, meta-analysis and mainly on 
glucose control and cost: decision was contrary to 
dispense new insulins in the SUS, even though recent 
robust reports clearly favor its use for DM1 [14, 15].
In conclusion, insulin analogue use at HRG-SHS/FD 
showed a little over than a quarter of patients achieved 
protocol glycemic targets of HbA1c <7.0 % and the same 
proportion had 0.5 % reduction. That implies the need 
to reevaluate both patients level of self-care knowledge 
and SBGM to be included in the dispense program, to 
detect early individual difficulties and limitations in 
order to provide education, proper and regular surveil-
lance by health professionals. Potential adjustments and 
improvement of participant enrollment in the SHS-FD 
protocol, based on the present data and study limita-
tions especially on larger DM2 inclusion, shall favor 
better glycemic control and quality of life in the near 
future and positive impact in the cost-benefit ratio of 
this pioneer national insulin analogue dispense program 
of the SUS-FD.
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